The case for & against
Bull & Bear analysis
Bullish
Bausch + Lomb Corporation (NYSE: BLCO) is a prominent player in the eye health sector, specializing in vision care and surgical solutions, along with pharmaceutical products designed to improve eye health. The company operates across various segments, including contact lenses, lens implants, and eye care pharmaceuticals. Positioned within an expanding market fueled by demographic shifts like aging populations and increasing occurrences of myopia, Bausch + Lomb aims to innovate and maintain competitive advantages, particularly in the therapeutic area of dry eye treatments.
Bull says
- ↑Q4 revenue reached $1.405B, up 7% YoY, with Adjusted EBITDA rising 28% to $330M.
- ↑Premium IOL sales soared 175% in Q2; Mibo prescriptions climbed 44%, boosting the dry-eye segment.
- ↑R&D investment jumped 19%, supporting new product launches and expanding pipeline.
- ↑Full-year adjusted EBITDA margin is guided to ~19%, reflecting ongoing margin expansion.
- ↑Q2 operating cash flow totaled $161M, underscoring strong cash generation and capital management.
- ↑Valuation factors show high earnings yield, strong book-to-price value, positive momentum, and effective leverage use.
Bear says
- ↓Weak profitability factors signal margin pressure and operational inefficiency.
- ↓Elevated revision risk reflects analyst doubts on meeting earnings targets.
- ↓Weak liquidity factors raise concerns over cash flow resilience.
- ↓Rising competition from JNJ, Alcon, AbbVie, and CooperCo pressures growth.
- ↓Insider sales of 52,900 shares signal potential management confidence issues.
- ↓Trade policy shifts and consumer spending pressures heighten macro risk.
Earnings Call · Q2 2025 · Mgmt. Guidance
Updated 08-21-2026neutral
Transcript signals
Bull points
- I think our contact lens portfolio of R&D projects is probably the best it's ever been in the history of the company.
- our R&D has been playing catch up to the market. And as part of our strategy, it was to now try to get into a lead the market.
- we saw the opportunity in the material innovation, and it has been for, as always, Brent said, it's like there's no innovation happened on the material side for so many years.
Bear points
- It's a long way of saying it's an unpredictable market. We can do better than we've done in the first half of the year.
- The Invista recall impacted our implantables business and parts of the equipment portfolio. Implantables declined by 16% in the quarter and equipment declined by 2%.
- Our U.S. generics business declined 29% in the quarter.
Read full transcript analysis ›